NCT01138111

Florbetaben (BAY94-9172) PET (Positron Emission Tomography) Imaging in MCI (Mild Cognitive Impairment) Patients

ß-amyloid Imaging With BAY94-9172 Positron Emission Tomography for Early Detection of Alzheimer's Disease in Patients With Mild Cognitive Impairment

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 45 (actual)
• Sponsor: Life Molecular Imaging SA · Industry
• Sex: All
• Age: 60 Years
• Healthy volunteers: Not accepted

Summary

The aim of the study is to investigate whether Florbetaben (BAY94-9172)positron emission tomography (PET) is able to distinguish between subjects with mild cognitive impairment (MCI) progressing to Alzheimer's disease (AD) from those with MCI not progressing to AD.

Conditions

• Alzheimer Disease
• Amyloid Beta-Protein

Interventions

Type	Name	Description
DRUG	Florbetaben (BAY94-9172)	single 300 megabecquerel (MBq) intravenous injection 2 mL to 10 mL, at baseline, at 12 and 24 months

Timeline

• Start date: 2008-06-01
• Primary completion: 2011-12-01
• Completion: 2011-12-01
• First posted: 2010-06-07
• Last updated: 2014-06-25
• Results posted: 2014-06-25

Locations

1 site across 1 country: Australia